# Case Report: Pregnant ROS1+ lung cancer patient treated with crizotinib - Impact on infancy

## TL;DR

A pregnant woman with lung cancer was treated with crizotinib and delivered a preterm infant, suggesting the drug may be safe for use during pregnancy.

## Contribution

Evidence that placental tissue reduces fetal crizotinib exposure, supporting its potential use during pregnancy.

## Key findings

- Crizotinib treatment during pregnancy resulted in preterm delivery but no fetal complications.
- Placental tissue significantly limits fetal exposure to crizotinib.
- Thromboembolic monitoring is crucial for pregnant cancer patients.

## Abstract

Lung cancer remains the leading cause of cancer-related deaths worldwide. Managing cancer treatment during pregnancy is a rare yet challenging condition, with limited data available on maternal and neonatal outcomes. We present the case of a 37-year-old pregnant woman diagnosed with ROS-1-rearranged metastatic NSCLC, who was treated with crizotinib and subsequently delivered a preterm infant. Our report underscores the critical need for rigorous thromboembolic monitoring in pregnant patients undergoing cancer treatment. Furthermore, we provide evidence that placental tissue significantly reduces fetal crizotinib exposure, suggesting that crizotinib might be a viable therapeutic option for maintaining a pregnancy during lung cancer treatment.